A major breakthrough in the treatment of Hepatitis B has offered fresh hope to millions of people worldwide. New clinical trials of an experimental drug called bepirovirsen have shown that around 20% of patients achieved a functional cure when the treatment was combined with standard antiviral therapy. The findings were recently published in the prestigious New England Journal of Medicine and presented at one of Europe's largest liver health conferences.
